Recent Quotes (30 days)

You have no recent quotes
chg | %

Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
135.87
-0.17 (-0.12%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 133.45 - 136.49
52 week 95.08 - 149.31
Open 135.45
Vol / Avg. 389,119.00/237,781.00
Mkt cap 2.86B
P/E 196.96
Div/yield     -
EPS 0.69
Shares 21.11M
Beta 0.91
Inst. own 118%
Feb 21, 2018
Q4 2017 Ligand Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 14, 2017
Ligand Pharmaceuticals Inc Analyst Day - Webcast
Nov 9, 2017
Q3 2017 Ligand Pharmaceuticals Inc Earnings Release
Nov 7, 2017
Ligand Pharmaceuticals Inc at Stephens Fall Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 25.25% -2.17%
Operating margin 49.42% 40.27%
EBITD margin - 51.58%
Return on average assets 5.19% -0.43%
Return on average equity 8.57% -0.82%
Employees 22 -
CDP Score - -

Address

3911 Sorrento Valley Blvd Ste 110
SAN DIEGO, CA 92121-1402
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Officers and directors

Matthew W. Foehr President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Matthew E. Korenberg Chief Financial Officer, Vice President - Finance
Age: 42
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
John W. Kozarich Non-Executive Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Nancy Ryan Gray Director
Age: 58
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 48
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 56
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters